Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 199

1.

Histological changes in patients who developed hepatocellular carcinoma after hepatitis C virus eradication by interferon-based therapy.

Kawaguchi T, Ide T, Kondo R, Nomura Y, Arinaga-Hino T, Kuwahara R, Amano K, Sano T, Akiba J, Ohshima K, Yano H, Torimura T.

Exp Ther Med. 2019 Nov;18(5):3991-4001. doi: 10.3892/etm.2019.8024. Epub 2019 Sep 18.

2.

Identification of heterozygous p.Y150C and p.V274M mutations in the HJV gene in a Japanese patient with a mild phenotype of juvenile hemochromatosis: A case report.

Kawaguchi T, Ikuta K, Tatsumi Y, Toki Y, Hayashi H, Tonan T, Ohtake T, Hoshino S, Naito M, Kato K, Okumura T, Torimura T.

Hepatol Res. 2019 Aug 31. doi: 10.1111/hepr.13423. [Epub ahead of print]

PMID:
31472034
3.

Questionnaire Survey from the 1st Kurume University Inflammatory Bowel Disease Center Educational Lecture.

Yamasaki H, Kinugasa T, Iwasaki S, Yoshioka S, Mizuochi T, Ishibashi M, Nagatsuka K, Yamauchi R, Ishibashi N, Araki T, Mori A, Akagi Y, Mitsuyama K, Torimura T.

Kurume Med J. 2019 Sep 25;65(3):109-112. doi: 10.2739/kurumemedj.MS653004. Epub 2019 Aug 9.

4.

Gastrointestinal: Abdominal pain, diarrhea, and bloody stools in a patient treated for renal cell carcinoma with sunitinib.

Fukunaga S, Mori A, Ohuchi A, Yoshioka S, Akiba J, Mistuyama K, Tsuruta O, Torimura T.

J Gastroenterol Hepatol. 2019 Jul 28. doi: 10.1111/jgh.14742. [Epub ahead of print] Review. No abstract available.

PMID:
31352682
5.

Infection phase is a predictor of pruritus in patients with hepatitis B virus infection.

Oeda S, Takahashi H, Isoda H, Komukai S, Imajo K, Yoneda M, Ono M, Hyogo H, Kawaguchi T, Fujii H, Kawanaka M, Sumida Y, Tanaka S, Kawamoto H, Torimura T, Saibara T, Kawaguchi A, Nakajima A, Eguchi Y.

Biomed Rep. 2019 Aug;11(2):63-69. doi: 10.3892/br.2019.1224. Epub 2019 Jun 21.

6.

Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH-HCC guidelines) 2019 update.

Kokudo N, Takemura N, Hasegawa K, Takayama T, Kubo S, Shimada M, Nagano H, Hatano E, Izumi N, Kaneko S, Kudo M, Iijima H, Genda T, Tateishi R, Torimura T, Igaki H, Kobayashi S, Sakurai H, Murakami T, Watadani T, Matsuyama Y.

Hepatol Res. 2019 Jul 23. doi: 10.1111/hepr.13411. [Epub ahead of print]

PMID:
31336394
7.

Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

Noda Y, Kawaguchi T, Kuromatsu R, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Torimura T.

Oncol Lett. 2019 Jul;18(1):227-236. doi: 10.3892/ol.2019.10285. Epub 2019 Apr 25.

8.

Slow walking speed overlapped with low handgrip strength in chronic liver disease patients with hepatocellular carcinoma.

Nagamatsu A, Kawaguchi T, Hirota K, Koya S, Tomita M, Hashida R, Kida Y, Narao H, Manako Y, Tanaka D, Koga N, Nakano D, Niizeki T, Matsuse H, Torimura T, Shiba N.

Hepatol Res. 2019 Jul 4. doi: 10.1111/hepr.13405. [Epub ahead of print]

PMID:
31273895
9.

Branched chain amino acids: A factor for zone 3 steatosis in non-alcoholic fatty liver disease.

Kawaguchi T, Torimura T.

Hepatol Res. 2019 Aug;49(8):841-843. doi: 10.1111/hepr.13402. No abstract available.

PMID:
31260576
10.

Immune-mediated Drug-induced Liver Injury Caused by Laninamivir Octanoate Hydrate.

Kawaguchi T, Arinaga-Hino T, Shimizu M, Tanikawa K, Tokushige T, Hirai S, Nagamatsu H, Tateishi H, Takata A, Ide T, Torimura T.

Intern Med. 2019 Sep 1;58(17):2501-2505. doi: 10.2169/internalmedicine.2740-19. Epub 2019 May 22.

11.

High serum interleukin-34 level is a predictor of poor prognosis in patients with non-viral hepatocellular carcinoma.

Noda Y, Kawaguchi T, Korenaga M, Yoshio S, Komukai S, Nakano M, Niizeki T, Koga H, Kawaguchi A, Kanto T, Torimura T.

Hepatol Res. 2019 Sep;49(9):1046-1053. doi: 10.1111/hepr.13350. Epub 2019 May 29.

PMID:
30993774
12.

Prognostic impact of transcatheter arterial chemoembolization (TACE) combined with radiofrequency ablation in patients with unresectable hepatocellular carcinoma: Comparison with TACE alone using decision-tree analysis after propensity score matching.

Shimose S, Tanaka M, Iwamoto H, Niizeki T, Shirono T, Aino H, Noda Y, Kamachi N, Okamura S, Nakano M, Kuromatsu R, Kawaguchi T, Kawaguchi A, Koga H, Yokokura Y, Torimura T.

Hepatol Res. 2019 Aug;49(8):919-928. doi: 10.1111/hepr.13348. Epub 2019 May 13.

PMID:
30969006
13.

[A Case of Chemotherapy-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Colon Cancer].

Tanaka T, Miwa K, Fukahori M, Yomoda T, Sakaue T, Nagasu S, Ushijima T, Koga H, Torimura T.

Gan To Kagaku Ryoho. 2019 Feb;46(2):259-262. Japanese.

PMID:
30914529
14.

Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: A prospective multicenter cohort study.

Nakano M, Koga H, Ide T, Kuromatsu R, Hashimoto S, Yatsuhashi H, Seike M, Higuchi N, Nakamuta M, Shakado S, Sakisaka S, Miuma S, Nakao K, Yoshimaru Y, Sasaki Y, Oeda S, Eguchi Y, Honma Y, Harada M, Nagata K, Mawatari S, Ido A, Maeshiro T, Matsumoto S, Takami Y, Sohda T, Torimura T.

Cancer Med. 2019 May;8(5):2646-2653. doi: 10.1002/cam4.2061. Epub 2019 Mar 22.

15.

Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study.

Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miuma S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, Torimura T.

Hepatol Int. 2019 May;13(3):293-301. doi: 10.1007/s12072-019-09939-2. Epub 2019 Feb 28.

PMID:
30820753
16.

Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer.

Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T, Ohta K, Nakamura KI, Torimura T.

Med Mol Morphol. 2019 Feb 25. doi: 10.1007/s00795-019-00218-5. [Epub ahead of print]

PMID:
30805710
17.

Clinical features of hepatocellular carcinoma in nonalcoholic fatty liver disease patients without advanced fibrosis.

Kodama K, Kawaguchi T, Hyogo H, Nakajima T, Ono M, Seike M, Takahashi H, Nozaki Y, Kawanaka M, Tanaka S, Imajo K, Sumida Y, Kamada Y, Fujii H, Seko Y, Takehara T, Itoh Y, Nakajima A, Masaki N, Torimura T, Saibara T, Karino Y, Chayama K, Tokushige K.

J Gastroenterol Hepatol. 2019 Sep;34(9):1626-1632. doi: 10.1111/jgh.14608. Epub 2019 Mar 6.

PMID:
30668889
18.

Dose and Location of Irradiation Determine Survival for Patients with Hepatocellular Carcinoma with Macrovascular Invasion in External Beam Radiation Therapy.

Iwamoto H, Nomiyama M, Niizeki T, Shimose S, Shirono T, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Sakai M, Suzuki H, Kuromatsu R, Ogo E, Abe T, Tanaka M, Koga H, Torimura T.

Oncology. 2019;96(4):192-199. doi: 10.1159/000495568. Epub 2019 Jan 16.

PMID:
30650415
19.

Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan.

Aiso M, Takikawa H, Tsuji K, Kagawa T, Watanabe M, Tanaka A, Sato K, Sakisaka S, Hiasa Y, Takei Y, Ohira H, Ayada M, Hashimoto E, Kaneko S, Ueno Y, Ohmoto K, Takaki A, Torimura T, Matsuzaki Y, Tajiri K, Yoneda M, Ito T, Kato N, Ikejima K, Mochida S, Yasuda H, Sakamoto N.

Hepatol Res. 2019 Jan;49(1):105-110. doi: 10.1111/hepr.13288.

PMID:
30565816
20.

Dipeptidyl Peptidase 4 Inhibitors Reduce Hepatocellular Carcinoma by Activating Lymphocyte Chemotaxis in Mice.

Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, Hino K.

Cell Mol Gastroenterol Hepatol. 2018 Sep 11;7(1):115-134. doi: 10.1016/j.jcmgh.2018.08.008. eCollection 2019.

21.

A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update.

Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K.

J Gastroenterol. 2019 Apr;54(4):367-376. doi: 10.1007/s00535-018-1532-5. Epub 2018 Nov 29.

22.

Non-alcoholic fatty liver disease in patients with autoimmune hepatitis.

Takahashi A, Arinaga-Hino T, Ohira H, Abe K, Torimura T, Zeniya M, Abe M, Yoshizawa K, Takaki A, Suzuki Y, Kang JH, Nakamoto N, Fujisawa T, Tanaka A, Takikawa H; Japan AIH Study Group (JAIHSG).

JGH Open. 2018 Mar 30;2(2):54-58. doi: 10.1002/jgh3.12046. eCollection 2018 Apr.

23.

Prediction of colorectal tumor grade and invasion depth through narrow-band imaging scoring.

Maeyama Y, Mitsuyama K, Noda T, Nagata S, Nagata T, Yoshioka S, Yoshida H, Mukasa M, Sumie H, Kawano H, Akiba J, Araki Y, Kakuma T, Tsuruta O, Torimura T.

World J Gastroenterol. 2018 Nov 14;24(42):4809-4820. doi: 10.3748/wjg.v24.i42.4809.

24.

Effects of in-hospital exercise on sarcopenia in hepatoma patients who underwent transcatheter arterial chemoembolization.

Koya S, Kawaguchi T, Hashida R, Hirota K, Bekki M, Goto E, Yamada M, Sugimoto M, Hayashi S, Goshima N, Yoshiyama T, Otsuka T, Nozoe R, Nagamatsu A, Nakano D, Shirono T, Shimose S, Iwamoto H, Niizeki T, Matsuse H, Koga H, Miura H, Shiba N, Torimura T.

J Gastroenterol Hepatol. 2019 Mar;34(3):580-588. doi: 10.1111/jgh.14538. Epub 2018 Dec 16.

PMID:
30402913
25.

Epirubicin is More Effective than Miriplatin in Balloon-Occluded Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma.

Shirono T, Iwamoto H, Niizeki T, Shimose S, Nakano M, Satani M, Okamura S, Noda Y, Kamachi N, Kuromatsu R, Sakai M, Nomiyama M, Kuwano T, Tanaka M, Koga H, Torimura T.

Oncology. 2019;96(2):79-86. doi: 10.1159/000492822. Epub 2018 Oct 5.

PMID:
30293080
26.

Health-related quality of life in patients with autoimmune hepatitis: A questionnaire survey.

Takahashi A, Moriya K, Ohira H, Arinaga-Hino T, Zeniya M, Torimura T, Abe M, Takaki A, Kang JH, Inui A, Fujisawa T, Yoshizawa K, Suzuki Y, Nakamoto N, Koike K, Yoshiji H, Goto A, Tanaka A, Younossi ZM, Takikawa H; Japan AIH Study Group.

PLoS One. 2018 Oct 4;13(10):e0204772. doi: 10.1371/journal.pone.0204772. eCollection 2018.

27.

Abdominal Pain and Prolonged Fever of Unknown Cause in a 14-Year-Old Boy.

Yoshitake M, Fukunaga S, Torimura T.

Gastroenterology. 2019 May;156(6):e1-e3. doi: 10.1053/j.gastro.2018.09.029. Epub 2018 Sep 18. No abstract available.

PMID:
30240664
28.

Ex vivo magnifying endoscopic observation of bile duct mucosa using narrowband imaging.

Ishida Y, Okabe Y, Yasumoto M, Naito Y, Nakama Y, Kitasato Y, Ishikawa H, Hisaka T, Tsuruta O, Torimura T.

J Hepatobiliary Pancreat Sci. 2018 Oct;25(10):433-439. doi: 10.1002/jhbp.581. Epub 2018 Oct 21.

PMID:
30218495
29.

Spontaneous regression of hepatocellular carcinoma with reduction in angiogenesis-related cytokines after treatment with sodium-glucose cotransporter 2 inhibitor in a cirrhotic patient with diabetes mellitus.

Kawaguchi T, Nakano D, Okamura S, Shimose S, Hayakawa M, Niizeki T, Koga H, Torimura T.

Hepatol Res. 2019 Apr;49(4):479-486. doi: 10.1111/hepr.13247. Epub 2018 Oct 1.

PMID:
30180287
30.

The characteristics of nivolumab-induced colitis: an evaluation of three cases and a literature review.

Yamauchi R, Araki T, Mitsuyama K, Tokito T, Ishii H, Yoshioka S, Kuwaki K, Mori A, Yoshimura T, Tsuruta O, Torimura T.

BMC Gastroenterol. 2018 Aug 31;18(1):135. doi: 10.1186/s12876-018-0864-1. Review.

31.

ADAPT: An Algorithm Incorporating PRO-C3 Accurately Identifies Patients With NAFLD and Advanced Fibrosis.

Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A, Karsdal MA, Grove JI, Neil Guha I, Kawaguchi T, Torimura T, McLeod D, Akiba J, Kaye P, de Boer B, Aithal GP, Adams LA, George J.

Hepatology. 2019 Mar;69(3):1075-1086. doi: 10.1002/hep.30163.

PMID:
30014517
32.

A Data Mining-based Prognostic Algorithm for NAFLD-related Hepatoma Patients: A Nationwide Study by the Japan Study Group of NAFLD.

Kawaguchi T, Tokushige K, Hyogo H, Aikata H, Nakajima T, Ono M, Kawanaka M, Sawada K, Imajo K, Honda K, Takahashi H, Mori K, Tanaka S, Seko Y, Nozaki Y, Kamada Y, Fujii H, Kawaguchi A, Takehara T, Yanase M, Sumida Y, Eguchi Y, Seike M, Yoneda M, Suzuki Y, Saibara T, Karino Y, Chayama K, Hashimoto E, George J, Torimura T.

Sci Rep. 2018 Jul 11;8(1):10434. doi: 10.1038/s41598-018-28650-0.

33.

High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.

Wada F, Koga H, Akiba J, Niizeki T, Iwamoto H, Ikezono Y, Nakamura T, Abe M, Masuda A, Sakaue T, Tanaka T, Kakuma T, Yano H, Torimura T.

Cancer Sci. 2018 Sep;109(9):2801-2810. doi: 10.1111/cas.13728. Epub 2018 Aug 16.

34.

Effects of isomaltulose on insulin resistance and metabolites in patients with non‑alcoholic fatty liver disease: A metabolomic analysis.

Kawaguchi T, Nakano D, Oriishi T, Torimura T.

Mol Med Rep. 2018 Aug;18(2):2033-2042. doi: 10.3892/mmr.2018.9223. Epub 2018 Jun 26.

35.

Cancer Lipid Metabolism Confers Antiangiogenic Drug Resistance.

Iwamoto H, Abe M, Yang Y, Cui D, Seki T, Nakamura M, Hosaka K, Lim S, Wu J, He X, Sun X, Lu Y, Zhou Q, Shi W, Torimura T, Nie G, Li Q, Cao Y.

Cell Metab. 2018 Jul 3;28(1):104-117.e5. doi: 10.1016/j.cmet.2018.05.005. Epub 2018 May 31.

36.

Endoscopic analysis of colorectal serrated lesions with cancer.

Nagata S, Mitsuyama K, Kawano H, Noda T, Maeyama Y, Mukasa M, Takedatsu H, Yoshioka S, Kuwaki K, Akiba J, Tsuruta O, Torimura T.

Oncol Lett. 2018 Jun;15(6):8655-8662. doi: 10.3892/ol.2018.8386. Epub 2018 Mar 29.

37.

[Treatment for sarcopenia in patients with chronic liver disease].

Kawaguchi T, Nakano D, Torimura T.

Nihon Shokakibyo Gakkai Zasshi. 2018;115(5):439-448. doi: 10.11405/nisshoshi.115.439. Japanese. No abstract available.

PMID:
29743452
38.

Marked accumulation of fluorodeoxyglucose and inflammatory cells expressing glucose transporter-3 in immunoglobulin G4-related autoimmune hepatitis.

Araki T, Arinaga-Hino T, Koga H, Akiba J, Ide T, Okabe Y, Kuwahara R, Amano K, Yasumoto M, Kawaguchi T, Sano T, Kondou R, Kurata S, Mitsuyama K, Torimura T.

Hepatol Res. 2018 Oct;48(11):937-944. doi: 10.1111/hepr.13188. Epub 2018 Jun 4.

PMID:
29737040
39.

Factors associated with advanced hepatic fibrosis in patients with various internal diseases: A multicenter community-based survey.

Kawaguchi T, Inokuchi T, Honma T, Itano S, Kawasaki E, Inada C, Aoki T, Tsumura N, Araki A, Mukae T, Torimura T.

Hepatol Res. 2018 Oct;48(11):882-892. doi: 10.1111/hepr.13190. Epub 2018 Jun 4.

PMID:
29736951
40.

Diagnostic and clinical role of serum proteinase 3 antineutrophil cytoplasmic antibodies in inflammatory bowel disease.

Takedatsu H, Mitsuyama K, Fukunaga S, Yoshioka S, Yamauchi R, Mori A, Yamasaki H, Kuwaki K, Sakisaka H, Sakisaka S, Torimura T.

J Gastroenterol Hepatol. 2018 Mar 7. doi: 10.1111/jgh.14140. [Epub ahead of print]

PMID:
29514409
41.

Clinical features of autoimmune hepatitis with acute presentation: a Japanese nationwide survey.

Joshita S, Yoshizawa K, Umemura T, Ohira H, Takahashi A, Harada K, Hiep NC, Tsuneyama K, Kage M, Nakano M, Kang JH, Koike K, Zeniya M, Yasunaka T, Takaki A, Torimura T, Abe M, Yokosuka O, Tanaka A, Takikawa H; Japan Autoimmune Hepatitis Study Group (JAIHSG).

J Gastroenterol. 2018 Sep;53(9):1079-1088. doi: 10.1007/s00535-018-1444-4. Epub 2018 Feb 23.

PMID:
29476251
42.

A case of gastric wall implantation caused by EUS-FNA 22 months after pancreatic cancer resection.

Yasumoto M, Okabe Y, Ishikawa H, Kisaki J, Akiba J, Naito Y, Ishida Y, Ushijima T, Tsuruta O, Torimura T.

Endosc Ultrasound. 2018 Jan-Feb;7(1):64-66. doi: 10.4103/eus.eus_58_17. No abstract available.

43.

Regulator of G-protein signaling 5 enhances portal vein invasion in hepatocellular carcinoma.

Umeno Y, Ogasawara S, Akiba J, Hattori S, Kusano H, Nakashima O, Koga H, Torimura T, Yamakawa R, Yano H.

Oncol Lett. 2018 Feb;15(2):1763-1770. doi: 10.3892/ol.2017.7474. Epub 2017 Nov 23.

44.

Surgically treated diaphragmatic perforation after radiofrequency ablation for hepatocellular carcinoma.

Nagasu S, Okuda K, Kuromatsu R, Nomura Y, Torimura T, Akagi Y.

World J Gastrointest Surg. 2017 Dec 27;9(12):281-287. doi: 10.4240/wjgs.v9.i12.281.

45.

Successful treatment of a patient with chyluria due to lymphangioleiomyomatosis using sirolimus.

Sakaue T, Tominaga M, Niizeki T, Zaizen Y, Matsukuma K, Koganemaru M, Hoshino T, Torimura T.

Respir Med Case Rep. 2018 Jan 5;23:86-89. doi: 10.1016/j.rmcr.2018.01.002. eCollection 2018.

46.

Clinical effects and safety of intra-arterial infusion therapy of cisplatin suspension in lipiodol combined with 5-fluorouracil versus sorafenib, for advanced hepatocellular carcinoma with macroscopic vascular invasion without extra-hepatic spread: A prospective cohort study.

Nakano M, Niizeki T, Nagamatsu H, Tanaka M, Kuromatsu R, Satani M, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan.

Mol Clin Oncol. 2017 Dec;7(6):1013-1020. doi: 10.3892/mco.2017.1442. Epub 2017 Oct 4.

47.

Electrical Stimulation of the Antagonist Muscle during Cycling Exercise Interval Training Improves Oxygen Uptake and Muscle Strength.

Hashida R, Takano Y, Matsuse H, Kudo M, Bekki M, Omoto M, Nago T, Kawaguchi T, Torimura T, Shiba N.

J Strength Cond Res. 2017 Dec 20. doi: 10.1519/JSC.0000000000002393. [Epub ahead of print]

PMID:
29278576
48.

A case of pancreatic neuroendocrine tumor with multiple cystic components of various sizes.

Yasumoto M, Okabe Y, Sugiyama G, Naito Y, Nakayama M, Hisaka T, Ishikawa H, Horiuchi H, Kunou Y, Ushijima T, Ishida Y, Tsuruta O, Torimura T.

Clin J Gastroenterol. 2018 Feb;11(1):87-91. doi: 10.1007/s12328-017-0798-0. Epub 2017 Dec 21.

PMID:
29270782
49.

Detection of calprotectin in inflammatory bowel disease: Fecal and serum levels and immunohistochemical localization.

Fukunaga S, Kuwaki K, Mitsuyama K, Takedatsu H, Yoshioka S, Yamasaki H, Yamauchi R, Mori A, Kakuma T, Tsuruta O, Torimura T.

Int J Mol Med. 2018 Jan;41(1):107-118. doi: 10.3892/ijmm.2017.3244. Epub 2017 Nov 7.

50.

STAT3 deficiency prevents hepatocarcinogenesis and promotes biliary proliferation in thioacetamide-induced liver injury.

Abe M, Yoshida T, Akiba J, Ikezono Y, Wada F, Masuda A, Sakaue T, Tanaka T, Iwamoto H, Nakamura T, Sata M, Koga H, Yoshimura A, Torimura T.

World J Gastroenterol. 2017 Oct 7;23(37):6833-6844. doi: 10.3748/wjg.v23.i37.6833.

Supplemental Content

Loading ...
Support Center